VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update

Core Insights - VYNE Therapeutics Inc. reported financial results for the quarter ended September 30, 2025, and provided a business update, focusing on its strategic review process to enhance shareholder value [1][2][3] Business Updates - The company initiated a strategic review in August 2025 to explore options for maximizing shareholder value, including evaluating its internal pipeline and potential strategic partnerships, licensing, mergers, or asset sales [3][6] - A repeat 12-week non-clinical toxicology study for VYN202 is ongoing, aimed at lifting the partial hold on testing in male clinical subjects for immuno-inflammatory diseases [2][6] - Cost reductions have been implemented to extend the company's cash runway into the first half of 2027 [3][6] Pipeline Overview - VYN202 is an oral small molecule BD2-selective BET inhibitor, showing promise in treating serious immune-mediated diseases and hematological cancers [5][7] - The FDA had previously placed a clinical hold on the Phase 1b trial of VYN202 due to observed testicular toxicity in dogs, but lifted the hold for female subjects in June 2025 [7] - Preliminary data from the Phase 1b trial in moderate-to-severe plaque psoriasis supports VYN202's potential as a disease-modifying therapy [7] Financial Results - As of September 30, 2025, VYNE had $32.7 million in cash, cash equivalents, and marketable securities, sufficient to fund operations into the first half of 2027 [10] - Revenues for the quarter totaled $0.2 million, an increase from $0.1 million in the same period in 2024, primarily from royalty revenue [11] - Research and development expenses decreased by 48.7% to $5.3 million compared to $10.2 million in Q3 2024, driven by reduced expenses for VYN202 and repibresib [12] - General and administrative expenses were $2.7 million, down 8.7% from $3.0 million in Q3 2024 [13] - The net loss for the quarter was $7.3 million, or $0.17 per share, compared to a net loss of $12.2 million, or $0.29 per share, in the same quarter of 2024 [14]